Ribomic Inc.
Announcement on Progress of Phase II Long-Term Dosing Trial of Umedaptanib Pegol for Achondroplasia and Continued Efficacy in Responding Patients
Reports progress of the Phase II long-term dosing trial and continued height growth effects in responding patients. AGV improvement was observed in patients with long-term dosing who responded, while non-responders showed no sustained effect. Monitor potential future dose adjustments. No impact on the fiscal year ending March 2027.
Key Figures
- AGV (Annualized Growth Velocity): Unknown
- Impact on results for the fiscal year ending March 2027 due to this matter: Unknown (not stated)
- Comparison between responding and non-responding cohorts: Unknown (quantitative data not published)
AI要約
Key Points
This report provides data on the progress of the Phase II long-term dosing trial of umedaptanib pegol and the continued efficacy observed in responding patients. It reports the trajectory of height growth velocity by dosing cohort and safety assessments. The responding cohort continued to show growth-promoting effects, whereas cohorts that did not achieve response showed no improvement in responsiveness. Future dose adjustment effects will be closely monitored.
Impact on Investors and Outlook
While cases of sustained response with long-term dosing have been confirmed, insufficient efficacy in non-responding cohorts may affect future clinical development strategy (dose optimization and reassessment of target populations). It is explicitly stated that there is no impact on results for the fiscal year ending March 2027.
Ribomic Inc.
Company overview · Stock price · Financial data · All IR
